TSRX raises cash, VVUS reiterates Avanafil NDA filing due 2Q, PPHM

May 25, 2011 No Comments by

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today announced the initiation of an investigator-sponsored trial (IST) for patients with castration-resistant prostate cancer (CRPC). 31 second-line CRPC patients will be treated with bavituximab in combination with the chemotherapeutic agent cabazitaxel.

VIVUS, Inc. (NASDAQ: VVUS) today reiterated that they plan to file their NDA for avanafil for the treatment of erectile dysfunction (ED) later this quarter.

Trius Therapeutics, Inc. (Nasdaq:TSRX), announced that it will receive gross proceeds of $30,162,500 in for the issuance of 4.75m shares of common stock and warrants to purchase 1,662,500 shares.

Daily News

About the author

Currently residing in New Zealand, Mr. A.Burden holds a Master of Commerce in International Business from the University of Sydney and used these skills together with his passion for investing to establish BioPharmCatalyst in June 2010 as a tool for investing decisions in the US pharmaceutical market. He spends much of his free time mountain biking, playing squash and hiking.
No Responses to “TSRX raises cash, VVUS reiterates Avanafil NDA filing due 2Q, PPHM”

Leave a Reply